FGFR2 Inhibition in Cholangiocarcinoma
Review on FGFR2 in Biliary tract cancer, in Annual review of medicine (2023), one of the most cited Europe PMC records with FGFR2 in its title.
Overview
Biliary tract cancer (BTC) is the second most common primary liver cancer after hepatocellular carcinoma and accounts for 2% of cancer-related deaths. BTCs are classified according to their anatomical origin into intrahepatic (iCCA), perihilar, or distal cholangiocarcinoma, as well as gall bladder carcinoma. While the mutational profiles in these anatomical BTC subtypes overlap to a large extent, iCCA is notable for the high frequency of IDH1/2 mutations (10-22%) and the nearly exclusive occurrence of FGFR2 fusions in 10-15% of patients. In recent years, FGFR2 fusions have become one of the most promising targets for precision oncology targeting BTC, with FGFR inhibitors already approved in Europe and the United States for patients with advanced, pretreated iCCA. While the therapeutic potential of nonfusion alterations is still under debate, it is expected that the field of FGFR2-directed therapies will be subject to rapid further evolution and optimization. The scope of this review is to provide an overview of oncogenic FGFR signaling in iCCA cells and highlight the pathophysiology, diagnostic testing strategies, and therapeutic promises and challenges associated with FGFR2-altered iCCA.
Indexed on Europe PMC as PubMed record 36170665 (DOI 10.1146/annurev-med-042921-024707). Its title names FGFR2 and its text names Biliary tract cancer; PubMed types it as a review (Research Support, Non-U.S. Gov't, Review). It was matched automatically to the idea "ctDNA-guided switching among FGFR inhibitors" and no figure has been checked by an editor.
One of the most cited reviews Europe PMC returns for FGFR2 in Biliary tract cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Matched by FGFR2 in the title and Biliary tract cancer in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.
- A review summarises other studies; the primary reports it cites are the evidence.